Longevity Evidence Lab Human evidence, uncertainty intact
Research interpretation, not diagnosis or personal treatment advice. Urgent symptoms belong with a clinician, not a browser tab.
Home / Evidence / Omega-3 fatty acids
Cardiometabolic

Omega-3 fatty acids

Some cardiovascular effects are real, but formulation, dose and baseline risk matter greatly.

The 30-second verdict Omega-3 is not one intervention. Dietary fish, mixed EPA/DHA supplements and high-dose prescription EPA have different evidence. Some analyses find modest reductions in selected cardiovascular events, while high-dose regimens may increase atrial fibrillation risk in susceptible populations. No reliable evidence supports generic fish-oil capsules as a universal life-extension treatment.

Evidence matrix

These scores describe different evidence domains. A strong mechanism cannot compensate for missing human outcomes, and a useful clinical effect need not imply slower biological ageing.

Human clinical outcomes Moderate
Human biomarkers Strong
Animal lifespan Preliminary
Mechanistic plausibility Strong
Safety certainty Moderate
Direct longevity relevance Limited

What has been shown in humans?

The strongest outcome evidence is cardiovascular and varies by formulation and risk group. Triglyceride lowering is well established, but changes in a biomarker do not guarantee fewer events. Evidence for cognition, mood and general inflammation is condition-specific and inconsistent.

What remains uncertain?

The relevance of blood omega-3 indices for treatment decisions, benefit in low-risk healthy adults, ideal EPA:DHA ratio and long-term balance between cardiovascular benefit and atrial fibrillation risk remain unsettled.

Doses used in research

Descriptive, not prescriptive Trials range from dietary advice and low-dose mixed oils to multi-gram prescription products. Results should not be transferred casually between these categories.

Safety and interpretation

  • Gastrointestinal effects and fishy aftertaste are common practical issues.
  • Higher doses may increase atrial fibrillation risk in people at high cardiovascular risk.
  • Bleeding risk and anticoagulant use require context, especially with prescription-dose products.

Primary sources and evidence reviews

Editorial note

This dossier was last reviewed on 13 July 2026. Ratings can change when larger trials, adverse-event data or better systematic reviews appear. Corrections should alter the page rather than being buried in a social-media thread.